ZHANG Qi, CHEN Min, ZHANG Shiqing. Conditional approval of medical devices in the United States and enlightenment[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
[1] USA Food and Drug Administration. Procedures for Handling Post-Approval Studies Imposed by Premarket Approval Application Order[EB/OL]. (2022-10-07)[2022-11-07]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/procedures-handling-post-approval-studies-imposed-pma-order. [2] USA Food and Drug Administration. Procedures for Handling Post-Approval Studies Imposed by Premarket Approval Application Order[EB/OL]. (2020-04-27)[2022-11-07]. https://www.fda.gov/media/83522/download. [3] USA Food and Drug Administration. Post-Approval Studies (PAS) Database(P200045)[EB/OL]. (2022-11-07)[2022-11-07]. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?tid=721614. [4] National Medical Products Administration.2021 Medical Device Registration Report of National Medical Products Administration[EB/OL]. (2022-01-27)[2022-11-07]. https://www.nmpa.gov.cn/yaowen/ypjgyw/20220127090648139.html. [5] General Office of the CPC Central Committee and The State Council. Opinions on Deepening the reform of the Review and Approval System and encouraging the innovation of drugs and medical devices [EB/OL]. (2017-10-08)[2022-11-07]. http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm. [6] The State Council. Regulations on the Supervision and Administration of Medical Devices[EB/OL]. (2021-02-09)[2022-11-07]. https://flk.npc.gov.cn/detail2.html?ZmY4MDgxODE3YjYzYjY3OTAxN2I3YWY3NDQ5MTM0YTM. [7] State Administration for Market Regulation. Measures for the Administration of registration and filing of medical devices[EB/OL]. (2021-08-31)[2022-11-07]. https://gkml.samr.gov.cn/nsjg/fgs/202108/t20210831_334228.html. [8] State Administration for Market Regulation. Measures for the Administration of registration and filing of IVD. [EB/OL]. (2021-08-31)[2022-11-07]. https://gkml.samr.gov.cn/nsjg/fgs/202108/t20210831_334228.html. [9] National Medical Products Administration. Guidelines for Conditional Marketing Approval of Medical Devices[EB/OL]. (2019-12-20)[2022-11-07]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20191220165501815.html. [10] National Medical Products Administration. Guidelines for the review of the registration of medical devices for the prevention and treatment of rare diseases [EB/OL]. (2018-10-18)[2022-11-07]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20181018162101924.html. [11] National Medical Products Administration. Medical device priority approval procedure [EB/OL]. (2018-10-18)[2022-11-07]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20181018162101924.html. [12] National Medical Products Administration. Medical device emergency approval procedures [EB/OL]. (2021-12-30)[2022-11-07]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20211230171343118.html. [13] USA Food and Drug Administration. Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval[EB/OL]. (2015-04-13)[2022-11-07]. https://www.fda.gov/media/88381/download. [14] JIANG HH.Current situation and future of medical device regulatory system based on product life cycle management[J]. China Food and Drug Regulation(中国食品药品监管), 2017(11): 60-62. [15] LIN Y.FDA premarket application path for medical combination products[J]. Chinese Journal of Medical Devices(中国医疗器械杂志), 2022, 46(4): 355-360, 364. [16] USA Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program[EB/OL]. (2022-11-09)[2022-11-10]. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/medical-product-safety-information.